IgA Nephropathy
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About IgA Nephropathy

What is the definition of IgA Nephropathy?
IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. End-stage kidney disease may develop. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection. Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23).
What are the alternative names for IgA Nephropathy?
  • IgA nephropathy
  • Berger disease
  • Berger's disease
  • Glomerulonephritis, IGA
  • IGAN
  • Nephritis, IGA type
Who are the top IgA Nephropathy Local Doctors?
Elite in IgA Nephropathy
Elite in IgA Nephropathy
Referral required

Georgia Nephrology

595 Hurricane Shoals Road Northwest, 
Lawrenceville, GA 
Languages Spoken:
English
Accepting New Patients

James Tumlin is a Nephrologist practicing medicine in Lawrenceville, Georgia. Dr. Tumlin is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Lupus Nephritis, Glomerulonephritis, Focal Segmental Glomerulosclerosis, and Kidney Transplant. Dr. Tumlin is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine - Nephrology. Dr. Tumlin is currently accepting new patients.

Elite in IgA Nephropathy
Elite in IgA Nephropathy
Referral may be required

CUIMC/Russ Berrie Medical Science Pavilion

1150 St. Nicholas Avenue, 
New York, NY 
Languages Spoken:
English

"Dr. Ali Gharavi is a kidney specialist with expertise in human genetics. He is the Harold Ames Hatch (II) Professor of Medicine and currently serves as Chair of the Department of Medicine at Columbia University Vagelos College of Physicians and Surgeons, and Physician-in-Chief, NewYork-Presbyterian Hospital/Columbia. He previously served as the Chief of the Division of Nephrology at NewYork-Presbyterian/Columbia University Irving Medical Center.The principal investigator on multiple research projects funded by the National Institutes of Health (NIH), Dr. Gharavi has specific interests in the genetics of kidney diseases, including IgA nephropathy and congenital abnormalities of the kidney and urinary tract. His research has identified genes and risk loci for many kidney diseases and has demonstrated the utility of sequencing for the diagnosis and management of patients with kidney disorders.""Owing to the recent progress in genomic technologies, we now have the opportunity to make a precise genetic diagnosis for many patients and individualize care based on the specific molecular mechanism of disease. My objective is to therefore bring personalized genomic medicine from the laboratory into patient care,"" says Dr. Gharavi. As Department Chair, he aims to enhance access to genomic medicine for patients and reduce disparities for underserved populations.After receiving his medical degree from George Washington University, Dr. Gharavi completed his Internal medicine residency at Mount Sinai Medical Center and fellowships in hypertension and nephrology, also at Mount Sinai. He then completed a postdoctoral fellowship in human genetics at Yale University School of Medicine. He previously held academic appointments at Yale University School of Medicine and Mount Sinai School of Medicine and hospital appointments at Mount Sinai Hospital. Dr. Gharavi is the author of over 200 peer-reviewed publications and has led national and International committees related to genetic testing and research for kidney disorders. He was a recipient of the Judson Daland Prize for Outstanding Clinical Investigation from the American Philosophical Society, the National Kidney Foundation Clinical Scientist Award, and Homer Smith Award from the American Society of Nephrology. He was elected to the American Society of Clinical Investigation and the American Association of Physicians.". Dr. Gharavi is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, and Kidney Transplant. Dr. Gharavi is board certified in Nephrology.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in IgA Nephropathy
Elite in IgA Nephropathy
Referral may be required

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
Languages Spoken:
English
Offers Telehealth

Richard Lafayette is a Nephrologist practicing medicine in Stanford, California. Dr. Lafayette is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Chronic Kidney Disease, and Kidney Transplant.

What are the latest IgA Nephropathy Clinical Trials?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Summary: In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage. Felzartamab...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Summary: This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combina...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center